Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

NEW YORK, Feb. 1, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that its peer-reviewed scientific manuscript entitled, "Bryostatin Placebo-Controlled Trials Indicate Cognitive Restoration Above Baseline for Advanced Alzheimer's Disease ("AD") in the Absence of Memantine" was published in the Journal of Alzheimer's Disease. The article documents evidence from two placebo-controlled trials that Bryostatin-1 improved cognition over baseline of advanced AD patients.

Read more at prnewswire.com